Skip to content

Serotonin: all studies

Page 325 of 401: studies 3,241 to 3,250 of 4,004, newest first. Back to the serotonin overview

Research

Neuronal reorganization in adult rats neonatally exposed to (±)-3,4-methylenedioxymethamphetamine

Toxicology Reports October 11, 2016 Michael T. Williams, Matthew R. Skelton, Ian D. Longacre et al. 3 citations

The abuse of methylenedioxymethamphetamine (MDMA) during pregnancy is of concern. MDMA treatment of rats during a period of brain growth analogous to late human gestation leads to neurochemical and behavioral changes. MDMA from postnatal day (P)11–20 in rats produces reductions in serotonin and deficits in spatial and route-based navigation. In this experiment we examined the impact of MDMA...

DOI: 10.1016/j.toxrep.2014.08.018 (opens in new tab) Full text (opens in new tab) Development Golgi–cox staining Dentate gyrus Entorhinal cortex

Psilocybin as an alternative medicine for patients suffering from depression

Psychiatria i Psychologia Kliniczna September 30, 2016 Karolina Dydak, Mariola Śliwińska‐mossoń, Halina Milnerowicz 2 citations

Psylocybina jest substancją psychodysleptyczną pochodzenia naturalnego, występuje w grzybach rodzaju Psilocybe. Psychodysleptyki są środkami psychoaktywnymi, które silnie wpływają na percepcję, nastrój i procesy poznawcze człowieka. Psychodeliczne działanie psylocybiny opiera się na pobudzaniu receptorów serotoninergicznych, co prowadzi do wzrostu stężenia serotoniny w mózgu oraz przyczynia się...

DOI: 10.15557/pipk.2016.0023 (opens in new tab) Psilocybin Depression economics Psychotherapist Hallucinogen

Australia should be initiating a psychedelic research program: What are the barriers?

Australian & New Zealand Journal of Psychiatry September 28, 2016 N. Strauss, Stephen Bright, Martin L Williams 10 citations

Australian & New Zealand Journal of Psychiatry, 50(11) A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research in North America and Europe as investigators at Johns Hopkins School of Medicine, University of California, Los Angeles (UCLA), New York University and Imperial College London have embarked on studies that...

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants

Translational Psychiatry September 20, 2016 Daniel M. Rotroff, Daniel Corum, Alison A. Motsinger‐Reif et al. 99 citations

Ketamine, at sub-anesthetic doses, is reported to rapidly decrease depression symptoms in patients with treatment-resistant major depressive disorder (MDD). Many patients do not respond to currently available antidepressants, (for example, serotonin reuptake inhibitors), making ketamine and its enantiomer, esketamine, potentially attractive options for treatment-resistant MDD. Although...

Comparative effects of amphetamine-like psychostimulants on rat hippocampal cell genesis at different developmental ages.

Neurotoxicology September 2016 Rubén García‐cabrerizo, M Julia García-Fuster

The aim of this study was to compare the effects of amphetamine-like psychostimulant drugs (i.e., MDMA, methamphetamine, D-amphetamine) on rat hippocampal cell genesis at different developmental ages (i.e., early adolescence vs. young adulthood) to determine if there were periods of vulnerability to drug-induced brain changes. Although adolescence is a period of great vulnerability to the...

Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain

EBioMedicine September 1, 2016 David Martin, Charles D. Nichols 88 citations

There has recently been a resurgence of interest in psychedelics, substances that profoundly alter perception and cognition and have recently demonstrated therapeutic efficacy to treat anxiety, depression, and addiction in the clinic. The receptor mechanisms that drive their molecular and behavioral effects involve activation of cortical serotonin 5-HT 2A receptors, but the responses of...

DOI: 10.1016/j.ebiom.2016.08.049 (opens in new tab) Parvalbumin Gabaergic Inhibitory postsynaptic potential

Aussiewaska: a cultural history of changa and ayahuasca analogues in Australia

September 1, 2016 Graham St John 3 citations

Introduction While the complexities of the global ayahuasca proliferation have drawn the attention of scholars in recent years, the cultural career of DMT (N,Ndimethyltryptamine) remains conspicuously under-researched. Most known for its role in the ayahuasca brew – where it is orally potentiated by beta-carboline harmala alkaloids contained in the liana Banisteriopsis caapi – the tryptamine...

The World Ayahuasca Diaspora

September 1, 2016 Graham St John 47 citations

While the complexities of the global ayahuasca proliferation have drawn the attention of scholars in recent years, the cultural career of DMT (N,Ndimethyltryptamine) remains conspicuously under-researched. Most known for its role in the ayahuasca brew – where it is orally potentiated by beta-carboline harmala alkaloids contained in the liana Banisteriopsis caapi – the tryptamine compound DMT...

Sex Differences in Abuse-Related Neurochemical and Behavioral Effects of 3,4-methylenedioxymethamphetamine (MDMA) in Rats

Pharmacology, Biochemistry, and Behavior August 24, 2016 Matthew F. Lazenka, J. Suyama, Clayton T. Bauer et al.

ABSTRACT 3,4‐Methylenedioxymethamphetamine (MDMA) is a substrate for dopamine (DA), norepinephrine and serotonin (5HT) transporters that produces greater pharmacological effects on certain endpoints in females than males in both clinical and rodent preclinical studies. To evaluate potential for sex differences in abuse‐related MDMA effects, the present study compared MDMA effects on...

Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.

Psychopharmacology Bulletin August 15, 2016 Edward C Lauterbach

Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.1,2 This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a...